BLTE · Belite Bio, Inc
$153.36
-1.57% last session
End-of-day data · updated 2026-07-28
Market cap
$6B
Enterprise value
—
Trailing P/E
—
Forward P/E
167.3
Dividend yield
—
Beta
-1.23
Avg volume
0M
Employees
0K
2D change
—
5D change
1.38%
10D change
5.56%
30D change
6.52%
60D change
9.88%
MTD change
11.33%
YTD change
-0.96%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — BLTE
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-15
Latest call per bank · past 12 months
Morgan Stanley
Overweight$201
+31.1% vs priceBank of America
Buy$195
+27.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-15 | HC Wainwright & Co. | Reiterates | Buy | $200 |
| 2026-05-26 | Mizuho | Maintains | Outperform | $223 → $215 |
| 2026-05-21 | HC Wainwright & Co. | Reiterates | Buy | $200 |
| 2026-04-22 | HC Wainwright & Co. | Reiterates | Buy | $200 |
| 2026-04-13 | HC Wainwright & Co. | Reiterates | Buy | $200 |
| 2026-03-03 | HC Wainwright & Co. | Maintains | Buy | $185 → $200 |
| 2026-03-03 | Morgan Stanley | Maintains | Overweight | $191 → $201 |
| 2026-03-03 | Cantor Fitzgerald | Maintains | Overweight | $200 → $266 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 55 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.2% above the 50-day MA ($146.89).
- Price vs 200-day MA: Trading 5.0% above the 200-day MA ($148.52).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is positive (+0.59) — short-term momentum is improving.
- 52-week range: Price sits between the 52-week low ($61.81) and high ($190.30).
BLTE Price Chart
Loading chart for BLTE…
Fundamentals
About Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.